PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.10
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.91
Net debt 50-75% of RVPH's 1.70. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
No Data
No Data available this quarter, please select a different quarter.
0.79
Current ratio 75-90% of RVPH's 0.90. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.